Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Libra

Showing results (11-20 of 293) with videos related to

Pageof 30
Sort By:
Cytokine|August 3, 2011
Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell linesSilvia Caggia, Massimo Libra, Grazia Malaponte, et al.
Oncology Reports|May 12, 2012
Breast cancer risk in women treated with augmentation mammoplasty (review)Alessio Stivala, Massimo Libra, Franca Stivala, et al.
Oncotarget|October 15, 2017
The miR-200 family in ovarian cancerMaria Koutsaki, Massimo Libra, Demetrios A Spandidos, et al.
Pharmaceutics|March 26, 2022
The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt PathwaysSaverio Candido, Rossella Salemi, Sara Piccinin, et al.
Antioxidants & Redox Signaling|July 19, 2023
Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products <i>via</i> the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic ImplicationsIndy Bui, Stavroula Baritaki, Massimo Libra, et al.
Cancers|October 3, 2019
Current Perspectives in Cancer ImmunotherapyTheodoulakis Christofi, Stavroula Baritaki, Luca Falzone, et al.
Cancer Biology & Therapy|December 3, 2005
Two targets are better than one. Promising combination therapy to treat breast cancerRichard A Franklin, Massimo Libra, Franca Stivala, et al.
Exploration of Targeted Anti-Tumor Therapy|May 19, 2023
Cancer resistance via the downregulation of the tumor suppressors <i>RKIP</i> and <i>PTEN</i> expressions: therapeutic implicationsMatthew Moghaddam, Silvia Vivarelli, Luca Falzone, et al.
Cancers|December 9, 2020
Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored TreatmentSilvia Vivarelli, Saverio Candido, Giuseppe Caruso, et al.
International Journal of Molecular Sciences|August 27, 2021
YY1 Silencing Induces 5-Fluorouracil-Resistance and <i>BCL2L15</i> Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic RelevanceSilvia Vivarelli, Luca Falzone, Saverio Candido, et al.
Pageof 30

Showing results (11-20 of 293) with videos related to

Sort By:
Pageof 30
Cytokine|August 3, 2011
Modulation of YY1 and p53 expression by transforming growth factor-β3 in prostate cell linesSilvia Caggia, Massimo Libra, Grazia Malaponte, et al.
Oncology Reports|May 12, 2012
Breast cancer risk in women treated with augmentation mammoplasty (review)Alessio Stivala, Massimo Libra, Franca Stivala, et al.
Oncotarget|October 15, 2017
The miR-200 family in ovarian cancerMaria Koutsaki, Massimo Libra, Demetrios A Spandidos, et al.
Pharmaceutics|March 26, 2022
The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt PathwaysSaverio Candido, Rossella Salemi, Sara Piccinin, et al.
Antioxidants & Redox Signaling|July 19, 2023
Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products <i>via</i> the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic ImplicationsIndy Bui, Stavroula Baritaki, Massimo Libra, et al.
Cancers|October 3, 2019
Current Perspectives in Cancer ImmunotherapyTheodoulakis Christofi, Stavroula Baritaki, Luca Falzone, et al.
Cancer Biology & Therapy|December 3, 2005
Two targets are better than one. Promising combination therapy to treat breast cancerRichard A Franklin, Massimo Libra, Franca Stivala, et al.
Exploration of Targeted Anti-Tumor Therapy|May 19, 2023
Cancer resistance via the downregulation of the tumor suppressors <i>RKIP</i> and <i>PTEN</i> expressions: therapeutic implicationsMatthew Moghaddam, Silvia Vivarelli, Luca Falzone, et al.
Cancers|December 9, 2020
Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored TreatmentSilvia Vivarelli, Saverio Candido, Giuseppe Caruso, et al.
International Journal of Molecular Sciences|August 27, 2021
YY1 Silencing Induces 5-Fluorouracil-Resistance and <i>BCL2L15</i> Downregulation in Colorectal Cancer Cells: Diagnostic and Prognostic RelevanceSilvia Vivarelli, Luca Falzone, Saverio Candido, et al.
Pageof 30